Research information, not medical advice. This page summarises published evidence and registered trials so that you can look further; it does not assess your situation. Talk to your own clinician before acting on anything here. How we select and grade sources
Based on: Gout — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 28 October 2026; the tracker page is the live version.
Full trial data → The Gout pipeline page on the Research Tracker has every candidate, gene target and trial, with evidence grades.
Short answer: as of October 2026, the OSMF Research Tracker lists 53 candidate medicines for gout that are either approved medicines or have at least one registered clinical trial, built on 5 druggable gene targets, with 15 recent trials on ClinicalTrials.gov. 9 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Febuxostat — 12 registered trials · approved medicine · NCT02060552 NCT02252835
- allopurinol — 11 registered trials · approved medicine · NCT01451645 NCT06056570 NCT01988402
- Canakinumab — 6 registered trials · approved medicine · NCT00798369
- Pegloticase — 6 registered trials · approved medicine · NCT02598596 NCT07388498 NCT04087720
- Colchicine — 5 registered trials · approved medicine · NCT02060552 NCT02252835 NCT02083510
- Lesinurad — 5 registered trials · approved medicine · NCT01493531 NCT01744379
- dotinurad — 3 registered trials · approved medicine · NCT06056570 NCT06834230 NCT07089888
- Arhalofenate — 3 registered trials · in clinical trials · NCT02252835 NCT01416402
- Methotrexate — 3 registered trials · in clinical trials · NCT07388498 NCT06229145 NCT03994731
- Triamcinolone acetonide — 2 registered trials · approved medicine · NCT00798369 NCT01356602
- ABP-671 — 2 registered trials · in clinical trials · NCT05818085 NCT04060173
- Allopurinol 300 mg — 2 registered trials · in clinical trials · NCT02063997 NCT03272425
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in gout and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: ABCG2, IL1B, NLRP3, SLC22A12, XDH.
Which trials are registered?
Drug and biologic treatment trials whose main condition is gout, from the tracker's ClinicalTrials.gov snapshot. Full trial data →
- A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout NCT07388498 · Recruiting · Phase 3 · started 2026-02-09
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) NCT06439602 · Completed · Phase 3 · started 2024-06-26
- Metformin in Safety and Efficacy in Gouty Patients NCT06924658 · Recruiting · Phase 2 · started 2025-04-20
- A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) NCT07280156 · Recruiting · Phase 2 · started 2025-12-22
- A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants NCT07535034 · Recruiting · Phase 2 · started 2026-05-08
- A Study of Dotinurad Versus Allopurinol in Tophaceous Gout NCT07089888 · Recruiting · Phase 3 · started 2025-08-04
- A Study of Dotinurad Versus Allopurinol in Participants With Gout NCT07089875 · Recruiting · Phase 3 · started 2025-08-01
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) NCT06846515 · Completed · Phase 3 · started 2025-03-11
- Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients NCT06995339 · Completed · Phase 2 · started 2025-05-30
- A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout NCT06229145 · Completed · Phase 4 · started 2024-03-18
- Tigulixostat (IBI128) vs Febuxostat in Gout NCT07414394 · Active Not Recruiting · Phase 3 · started 2026-03-17
- Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout NCT07752810 · Completed · Phase 1/2 · started 2022-06-23
- SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial NCT06674109 · Recruiting · Phase 4 · started 2026-07-01
- A Study of IN026 in Participants With Refractory Gout NCT07587684 · Recruiting · Phase 1 · started 2026-06-12
- Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects NCT07346027 · Active Not Recruiting · Phase 1 · started 2026-06-25
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The list is restricted to medicines and supplements: trial arms that are devices, procedures, behavioural programmes or measurements are filtered out automatically, so an occasional misclassified entry is possible; the tracker page lists every arm. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take. How sources are chosen, graded and corrected is set out in our editorial policy.
More Metabolic Health notes
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 28 October 2026.